Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4280A versus physician's choice chemotherapy in relapsed or refractory classical Hodgkin lymphoma after prior PD-1/PD-L1 therapy
MOH_2022-07-03_010824Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of favezelimab + pembrolizumab, favezelimab and pembrolizumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Jun 2022; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on MOH_2022-07-03_010824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-03_010824.